Applied Genetic Technologies Co. (NASDAQ:AGTC) Receives Average Recommendation of “Buy” from Brokerages

Shares of Applied Genetic Technologies Co. (NASDAQ:AGTCGet Rating) have earned an average recommendation of “Buy” from the eight analysts that are currently covering the stock, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and six have assigned a buy rating to the company. The average 12 month price target among brokerages that have issued a report on the stock in the last year is $15.00.

Several equities research analysts have recently weighed in on AGTC shares. Chardan Capital reissued a “buy” rating on shares of Applied Genetic Technologies in a research report on Monday. StockNews.com started coverage on Applied Genetic Technologies in a research report on Thursday, March 31st. They set a “sell” rating on the stock. Roth Capital reissued a “buy” rating on shares of Applied Genetic Technologies in a research report on Tuesday, February 8th. Finally, Stifel Nicolaus cut their price target on Applied Genetic Technologies to $10.00 and set a “buy” rating on the stock in a research report on Monday, February 14th.

Shares of AGTC opened at $1.10 on Friday. The stock has a 50-day simple moving average of $1.68 and a 200-day simple moving average of $2.06. The company has a debt-to-equity ratio of 0.26, a quick ratio of 3.13 and a current ratio of 3.13. The stock has a market capitalization of $47.21 million, a PE ratio of -0.72 and a beta of 1.67. Applied Genetic Technologies has a 1 year low of $0.96 and a 1 year high of $4.65.

Applied Genetic Technologies (NASDAQ:AGTCGet Rating) last announced its quarterly earnings data on Monday, February 14th. The biotechnology company reported ($0.45) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.38) by ($0.07). During the same quarter last year, the firm posted ($0.60) earnings per share. Analysts predict that Applied Genetic Technologies will post -1.65 EPS for the current year.

Several hedge funds have recently added to or reduced their stakes in AGTC. Millennium Management LLC increased its holdings in shares of Applied Genetic Technologies by 26.0% in the 4th quarter. Millennium Management LLC now owns 1,533,193 shares of the biotechnology company’s stock valued at $2,913,000 after purchasing an additional 316,276 shares in the last quarter. BlackRock Inc. increased its holdings in shares of Applied Genetic Technologies by 6.4% in the 4th quarter. BlackRock Inc. now owns 1,105,950 shares of the biotechnology company’s stock valued at $2,101,000 after purchasing an additional 66,771 shares in the last quarter. Geode Capital Management LLC increased its holdings in shares of Applied Genetic Technologies by 5.3% in the 4th quarter. Geode Capital Management LLC now owns 630,006 shares of the biotechnology company’s stock valued at $1,197,000 after purchasing an additional 31,847 shares in the last quarter. GSA Capital Partners LLP increased its holdings in shares of Applied Genetic Technologies by 366.5% in the 3rd quarter. GSA Capital Partners LLP now owns 583,510 shares of the biotechnology company’s stock valued at $1,756,000 after purchasing an additional 458,420 shares in the last quarter. Finally, Two Sigma Advisers LP increased its holdings in shares of Applied Genetic Technologies by 152.4% in the 3rd quarter. Two Sigma Advisers LP now owns 327,129 shares of the biotechnology company’s stock valued at $985,000 after purchasing an additional 197,500 shares in the last quarter. Institutional investors own 35.02% of the company’s stock.

About Applied Genetic Technologies (Get Rating)

Applied Genetic Technologies Corporation, a clinical-stage biotechnology company, develops transformational genetic therapies for patients suffering from rare and debilitating diseases. Its advanced product candidates include three ophthalmology development programs across two targets, including X-linked retinitis pigmentosa, which is in the Phase I/II clinical trials; and achromatopsia that is in Phase I/II clinical trials.

See Also

Analyst Recommendations for Applied Genetic Technologies (NASDAQ:AGTC)

Receive News & Ratings for Applied Genetic Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Applied Genetic Technologies and related companies with MarketBeat.com's FREE daily email newsletter.